Skip to main content

Table 2 Study characteristics of the two included studies

From: Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: a systematic review

Study characteristics

 

Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma

A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis

First author

Gevaert

Pinto

Publication year

2013

2010

Country

Belgium

USA

Funding source

Ghent University, Flemish Scientific Research Board, Belgian Research Fund, Interuniversity Attraction Poles Program, Global Allergy and Asthma European Network, Novartis

Genentech and McHugh Research Fund, Dennis W. Jahnigen Career Development Award (American Geriatrics Society)

Study design

RCT

RCT

Inclusion criteria

Age ≥18 with CRSwNP, comorbid asthma for >2 years, serum IgE between 30 and 700 kU/mL

Age 18–75, >12 weeks of symptoms with confirmation on CT and nasal endoscopy, serum IgE between 30 and 700 kU/mL

Exclusion criteria

N/A

Weight >150 kg, secondary causes of CRS, contraindications to omalizumab

No. of subjects randomized

24

14

No. of subjects excluded

4

0

No. of subjects withdrawn

1

0

No. of subjects analyzed

Total (n) = 23

Total (n) = 14

Men (n) = N/A

Men (n) = 10

Women (n) = N/A

Women (n) = 4

Age

Mean = N/A

Mean = 45.85

Median = N/A

Median = N/A

Range = 42–56

Range = N/A

Drug dose

Max dose of 375 mg

0.016 mg/kg per IU total serum IgE/mL

Dosing frequency

Every 2 weeks (eight injections in total); every month (four injections in total)

At enrollment and every 4 weeks for the 6 months duration

Study duration

20 weeks (16 weeks follow-up)

6 months

  1. RCT randomized controlled trial, CRS chronic rhinosinusitis, N/A not available